Newsletter Subject

Could this Healthcare Stock really climb 1,368.75% in 2024?

From

marketinsiderspress.com

Email Address

editor@marketinsiderspress.com

Sent On

Mon, Feb 12, 2024 07:47 PM

Email Preheader Text

Earnings Alert. If you cannot see this email properly, please click --------------------------------

Earnings Alert. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Gold Could Be Heading for Record Highs - But How to Play It?]( [See this little-known way to play in the rising gold market.]( --------------------------------------------------------------- February 12, 2024 (Earnings Report) From the desk of the Editor Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements. --------------------------------------------------------------- Sponsor Message [The Strategic Gold Play You Haven't Heard About]( recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. [Get the full story on this overlooked gold investment strategy here.]( --------------------------------------------------------------- [Roivant Sciences Ltd.]( Symbol: [ROIV]( Recent Price: $10.81 Average Analyst Price Target: $15.33 (41.84%) Market Cap: $8.69B Last Year's EPS: $-0.38 Consensus EPS Forecast: $-0.28 Expected Earnings Date: Feb 13, 2024 Recent Analyst Action: Allison Bratzel, analyst at Piper Sandler, reiterates coverage on [Roivant Sciences Ltd. (ROIV)]( in the Healthcare sector with a Buy rating and a price target of $20 (1 month ago). [TipRanks.com]( also reports that [Roivant Sciences Ltd.]( currently has 3 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $15.33 . The target pricing ranges from a high forecast of $20 down to a low forecast of $12. [Roivant Sciences Ltd. (ROIV)](’s last closing price was $10.81 which would put the average price target at 41.84% upside. Here are 3rd party ratings for [ROIV](: - TipRanks.com: Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Top 39% (97 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [URGENT: Don't risk your retirement]( looming recession, inflation, unpayable debt, a failing dollar, and a crumbling housing market all put your savings in extreme risk. Protect your retirement with this free guide that shows you how to guard your money against economic downturns with gold. Take action NOW, before it’s too late, Download your free guide and see for yourself why gold is the #1 safe haven for smart investors. [Protect your retirement with this free gold guide]( --------------------------------------------------------------- [Nurix Therapeutics, Inc.]( Symbol: [NRIX]( Recent Price: $8.85 Average Analyst Price Target: $30.60 (245.76%) Market Cap: $429.26M Last Year's EPS: $-0.45 Consensus EPS Forecast: $-0.69 Expected Earnings Date: Feb 13, 2024 Recent Analyst Action: Joseph Catanzaro, analyst at Piper Sandler, reiterates coverage on [Nurix Therapeutics, Inc. (NRIX)]( in the Healthcare sector with a Buy rating and a price target of $35 (1 week ago). [TipRanks.com]( also reports that [Nurix Therapeutics, Inc.]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $30.60 . The target pricing ranges from a high forecast of $35 down to a low forecast of $24. [Nurix Therapeutics, Inc. (NRIX)](’s last closing price was $8.85 which would put the average price target at 245.76% upside. Here are 3rd party ratings for [NRIX](: - TipRanks.com: Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: buy - Zacks.com: Sell, Top 39% (97 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- [Cybin Inc.]( Symbol: [CYBN]( Recent Price: $0.32 Average Analyst Price Target: $4.70 (1,368.75%) Market Cap: $130.83M Last Year's EPS: $-0.05 Consensus EPS Forecast: $-0.05 Expected Earnings Date: Feb 13, 2024 Recent Analyst Action: Francois Brisebois, analyst at Oppenheimer, reiterates coverage on [Cybin Inc. (CYBN)]( in the Healthcare sector with a Buy rating and a price target of $4.5 (1 month ago). [TipRanks.com]( also reports that [Cybin Inc.]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $4.70 . The target pricing ranges from a high forecast of $6 down to a low forecast of $3. [Cybin Inc. (CYBN)](’s last closing price was $0.32 which would put the average price target at 1,368.75% upside. Here are 3rd party ratings for [CYBN](: - TipRanks.com: Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Sell, Top 39% (97 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Here’s How The REAL Money Is Made In The Markets]( - Illegal insider trading… - Risky quarterly earnings bets… - Slow and boring “buy and hold”... - [CLICK TO SEE]( You’ll wish you thought of this sooner. [>> Watch the 90 second video.]( --------------------------------------------------------------- [Presto Automation, Inc.]( Symbol: [PRST]( Recent Price: $0.20 Average Analyst Price Target: $1.37 (586.67%) Market Cap: $13.35M Last Year's EPS: $-0.78624 Consensus EPS Forecast: $-0.24 Expected Earnings Date: Feb 13, 2024 Recent Analyst Action: Samad Samana, analyst at Jefferies, reiterates coverage on [Presto Automation, Inc. (PRST)]( in the Technology sector with a Hold rating and a price target of $0.62 (1 month ago). [TipRanks.com]( also reports that [Presto Automation, Inc.]( currently has 3 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $1.37 . The target pricing ranges from a high forecast of $2 down to a low forecast of $0.62. [Presto Automation, Inc. (PRST)](’s last closing price was $0.20 which would put the average price target at 586.67% upside. Here are 3rd party ratings for [PRST](: - TipRanks.com: Hold - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 39% (97 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- [Electromed, Inc.]( Symbol: [ELMD]( Recent Price: $10.38 Average Analyst Price Target: $20.50 (97.50%) Market Cap: $89.08M Last Year's EPS: $0.12 Consensus EPS Forecast: $0.1 Expected Earnings Date: Feb 13, 2024 Recent Analyst Action: Brooks O'Neil, analyst at Lake Street, reiterates coverage on [Electromed, Inc. (ELMD)]( in the Healthcare sector with a Buy rating and a price target of $26 (2 months ago). [TipRanks.com]( also reports that [Electromed, Inc.]( currently has 2 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $20.50 . The target pricing ranges from a high forecast of $26 down to a low forecast of $15. [Electromed, Inc. (ELMD)](’s last closing price was $10.38 which would put the average price target at 97.50% upside. Here are 3rd party ratings for [ELMD](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: n/a, n/a [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Musk: My new robots could be bigger than Tesla]( No one can deny Elon Musk is a visionary. But has he finally gone too far? [>>See the shocking future of AI here<<]( --------------------------------------------------------------- [AutoNation, Inc.]( Symbol: [AN]( Recent Price: $152.17 Average Analyst Price Target: $178.20 (17.11%) Market Cap: $6.47B Last Year's EPS: $6.29 Consensus EPS Forecast: $5.49 Expected Earnings Date: Feb 13, 2024 Recent Analyst Action: Douglas Dutton, analyst at Evercore ISI, reiterates coverage on [AutoNation, Inc. (AN)]( in the Consumer Cyclical sector with a Buy rating and a price target of $185 (3 weeks ago). [TipRanks.com]( also reports that [AutoNation, Inc.]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $178.20 . The target pricing ranges from a high forecast of $255 down to a low forecast of $142. [AutoNation, Inc. (AN)](’s last closing price was $152.17 which would put the average price target at 17.11% upside. Here are 3rd party ratings for [AN](: - TipRanks.com: Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Bottom 10% (224 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- [Primerica, Inc.]( Symbol: [PRI]( Recent Price: $242.46 Average Analyst Price Target: $216.25 (-10.81%) Market Cap: $8.49B Last Year's EPS: $3.99 Consensus EPS Forecast: $4.03 Expected Earnings Date: Feb 13, 2024 Recent Analyst Action: Wilma Burdis, analyst at Raymond James, reiterates coverage on [Primerica, Inc. (PRI)]( in the Financial Services sector with a Hold rating (9 hours ago). [TipRanks.com]( also reports that [Primerica, Inc.]( currently has 4 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $216.25 . The target pricing ranges from a high forecast of $260 down to a low forecast of $200. [Primerica, Inc. (PRI)](’s last closing price was $242.46 which would put the average price target at -10.81% upside. Here are 3rd party ratings for [PRI](: - TipRanks.com: Hold - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Buy, Top 19% (48 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Americans Now Favor Gold Over Stocks as an Investment Vehicle]( now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges. [See why investors are so impressed by this overlooked gold investment strategy.]( --------------------------------------------------------------- And there you have it--- Stocks expected to release earnings soon... Sincerely, The Editor, MarketInsidersPress.com MarketInsidersPress.com Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. [If you are not a human, click here.]( By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. This is part of your free subscription to MarketInsidersPress.com MarketInsidersPress.com part of Sandpiper Marketing Group, LLC 165 Lockerbie Lane | Mooresville NC | 28115 MarketInsidersPress.com part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mount Mourne | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software

Marketing emails from marketinsiderspress.com

View More
Sent On

09/05/2024

Sent On

09/05/2024

Sent On

09/05/2024

Sent On

08/05/2024

Sent On

08/05/2024

Sent On

08/05/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.